Prevail Therapeutics Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Prevail Therapeutics (PRVL) IPO Opens Lower
June 20, 2019 12:45 PM EDTToday's IPO for Prevail Therapeutics Inc. (Nasdaq: PRVL) opened for trading at $15.31 after pricing 7,353,000 shares of its common stock at a price to the public of $17.00 per share.
In addition, Prevail has granted the underwriters a 30-day option to purchase up to an... More
